4-氯-2-羟基苯甲酸甲酯 | 22717-55-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氯-2-羟基苯甲酸甲酯
• 中文别名: 4-氯水杨酸甲酯
• 英文名称: methyl 4-chloro-2-hydroxybenzoate
• 英文别名: methyl 4-chlorosalicylate；methyl 2-hydroxy-4-chlorobenzoate；4-Chlor-2-hydroxy-benzoesaeure-methylester
• CAS: 22717-55-1
• 化学式: C₈H₇ClO₃
• mdl: MFCD03407436
• 分子量: 186.595
• InChiKey: QXDWMJQRXWLSDP-UHFFFAOYSA-N

物化性质

• 沸点：
  127 °C(Press: 15 Torr)
• 密度：
  1.354±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2918290000
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  应存放在室温、密封和干燥的环境中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 4-chloro-2-hydroxybenzoate
Synonyms: Methyl 4-chlorosalicylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 4-chloro-2-hydroxybenzoate
CAS number: 22717-55-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H7ClO3
Molecular weight: 186.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氯-2-羟基苯甲酸甲酯 在 异丙醇 作用下， 反应 72.0h， 以70%的产率得到水杨酸甲酯
  参考文献：
  名称：

  用于用可见光解锁有机卤化物的陶瓷碳氮化硼

  摘要：

  光化学通过电子转移过程从底物中诱导自由基中间体，为有机转化提供了可持续的途径。然而，进展受到多相光催化剂的限制，这些光催化剂需要高效、稳定、廉价才能长期运行，并且易于回收和产品分离。在这里，我们报道碳氮化硼（BCN）陶瓷就是这样一个系统，可以在可见光照射下减少有机卤化物，包括（杂）芳基和烷基卤化物。卤化物的交叉偶联可在环境反应条件下进行，以提供新的 C-H、C-C 和 C-S 键。在没有任何金属基催化剂或配体的情况下，通过介晶 C-X（碳-卤素）键断裂将氢、（杂）芳基和磺酰基引入芳烃和杂芳烃的设计位置。 BCN不仅可用于半反应，例如与牺牲剂的还原反应，还可用于通过氧化和还原界面电子转移的氧化还原反应。 BCN 光催化剂表现出对不同取代基的耐受性，并且在五次回收后活性保持不变。这种表面上不含金属的系统为使用光能和可持续材料的各种有机催化剂开辟了新的机遇，这些催化剂不含金属、廉价且稳定。

  DOI：

  10.1039/d1sc01028j
• 作为产物：
  描述：

  水杨酸甲酯 在 碘 氯 作用下， 反应 2.5h， 以96%的产率得到4-氯-2-羟基苯甲酸甲酯
  参考文献：
  名称：

  Simonov, V. D.; Ivanov, V. I.; Galeeva, A. B., Journal of applied chemistry of the USSR, 1981, vol. 54, # 4, p. 771 - 772

  摘要：

  DOI：

文献信息

• [EN] NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS<br/>[FR] DERIVES DE NICOTINAMIDE UTILES EN TANT QU'INHIBITEURS DE PDE4
  申请人：PFIZER LTD

  公开号：WO2005009965A1

  公开（公告）日：2005-02-03

  This invention relates to nicotinamide derivative of general formula (I), in which R1, R2 and R3 have the meanings defined herein, and to compositions containing and the uses of such derivatives as PDE4 inhibitors.

  这项发明涉及一般式(I)的烟酰胺衍生物，其中R1、R2和R3具有本文中定义的含义，以及含有这些衍生物并将其用作PDE4抑制剂的组合物。
• 유기전기 소자용 화합물을 이용한 유기전기소자 및 그 전자 장치
  申请人：DUK SAN NEOLUX CO., LTD. 덕산네오룩스 주식회사(120150011099) Corp. No ▼ 161511-0176036BRN ▼312-86-74729

  公开号：KR20150031892A

  公开（公告）日：2015-03-25

  본 발명은 소자의 발광효율, 안정성 및 수명을 향상시킬 수 있는 화합물을 이용한 유기전기소자, 그 전자 장치를 제공한다.

  这项发明提供了一种利用化合物可以提高器件的发光效率、稳定性和寿命的有机电子器件及其电子装置。
• 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用
  申请人：广州必贝特医药股份有限公司

  公开号：CN113480534B

  公开（公告）日：2022-05-13

  本发明公开了一种苯并咪唑或氮杂苯并咪唑‑6‑羧酸类化合物及其应用，所述苯并咪唑或氮杂苯并咪唑‑6‑羧酸类化合物具有式(I)所示结构。该苯并咪唑或氮杂苯并咪唑‑6‑羧酸类化合物可以有效激活GLP‑1R下游信号通路，提高cAMP的表达，从而达到促进胰岛素分泌，治疗糖尿病及其并发症的作用，有较大的应用价值。
• Synthesis and biological evaluation of novel 5,6,7-trimethoxy flavonoid salicylate derivatives as potential anti-tumor agents
  作者：Renbo Liu、Xiangping Deng、Yijiao Peng、Wanshi Feng、Runde Xiong、Yang Zou、Xiaoyong Lei、Xing Zheng、Zhizhong Xie、Guotao Tang

  DOI：10.1016/j.bioorg.2020.103652

  日期：2020.3

  5,6,7-Trimethoxy flavonoid salicylate derivatives were designed by the joining of three important pharmacophores (TMP, flavonoid, and SA) according to the combination principle. A series of novel trimethoxy flavonoid salicylate derivatives were synthesized and their in vitro anti-tumor activities were evaluated. Among these derivatives, compound 7f exhibited excellent antiproliferative activity against

  通过结合三种重要的药效团（TMP，类黄酮和SA），设计了5,6,7-三甲氧基黄酮类水杨酸酯衍生物。合成了一系列新型三甲氧基黄酮水杨酸酯衍生物，并对其体外抗肿瘤活性进行了评估。在这些衍生物中，化合物7f对HGC-27细胞和MGC-803细胞表现出优异的抗增殖活性，IC50值分别为10.26±6.94μM和17.17±3.03μM。随后，对细胞集落形成（克隆形成存活测定），细胞迁移（伤口愈合测定），细胞周期分布（PI染色测定），细胞凋亡（Hoechst 33258染色测定和膜联蛋白V-FITC / PI双重染色测定）的影响，乳酸水平（乳酸测量），确定微管排列失调（免疫荧光染色分析）和对接姿势（分子对接模拟）。进一步的蛋白质印迹分析证实，化合物7f可以有效下调糖酵解相关蛋白HIF-1α，PFKM和PKM2以及肿瘤血管生成相关蛋白VEGF的表达。总体而言，这些研究表明，化合物7f作为其中的代表性化
• [EN] SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF<br/>[FR] COMPOSÉS HÉTÉRO-BICYCLIQUES SUBSTITUÉS, COMPOSITIONS ET LEURS APPLICATIONS MÉDICINALES
  申请人：ADVINUS THERAPEUTICS LTD

  公开号：WO2013157022A1

  公开（公告）日：2013-10-24

  The present disclosure provides hetero-biclyclic compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, hydrates, N-oxides, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by Bruton's tyrosine kinase (Btk) activity, The disclosure also relates to the process of preparation of compounds of Formula (I). These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of Bruton's tyrosine kinase (Btk), such as inflammatory and/or autoimmune disorder, cell proliferation, rheumatoid arthritis, psoriasis, psoriatic arthritis, transplant rejection, graft-versus-host disease, multiple sclerosis, inflammatory bowel disease, allergic diseases, asthma, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, B-cell malignancies, systemic lupus, erythematosus or other disorders.

  本公开提供了式(I)的杂环双环化合物，它们的互变异构体、多晶形态、立体异构体、前药、溶剂合物、水合物、N-氧化物、共晶体、药学上可接受的盐、含有它们的药物组合物以及治疗由布鲁顿酪氨酸激酶（Btk）活性介导的疾病和病症的方法。该公开还涉及制备式(I)化合物的过程。这些化合物在治疗、预防、预防、管理或辅助治疗与抑制布鲁顿酪氨酸激酶（Btk）有关的所有医学状况方面具有用处，如炎症和/或自身免疫性疾病、细胞增殖、类风湿关节炎、牛皮癣、银屑病性关节炎、移植排斥、移植物抗宿主病、多发性硬化、炎症性肠病、过敏性疾病、哮喘、1型糖尿病、重症肌无力、造血功能障碍、B细胞恶性肿瘤、系统性红斑狼疮或其他疾病。